Despite 20 years of controversy, the definitive answer as to whether newer contraceptive pills further increase venous thromboembolism risk remains elusive
The 19th century German physician Rudolf Virchow described the mechanism of venous thromboembolism (VTE) in terms of interactions between haemodynamics, vein wall disruption and hypercoagulability. An understanding of this interplay is particularly important in a women’s health context since changes in the hormonal milieu, such as those seen in pregnancy and the use of exogenous oestrogen therapy, may act in concert to further increase VTE risk.
The full article is accessible to AMA members and paid subscribers. Login to read more or purchase a subscription now.
Please note: institutional and Research4Life access to the MJA is now provided through Wiley Online Library.
I have been a member of a number of advisory committees for MSD and Bayer — both of which market COCPs in Australia. I have developed educational material for educational sessions sponsored by MSD and Bayer, and accepted an honorarium on these occasions. I have accepted sponsorship from a number of pharmaceutical companies to enable me to attend and present at conferences relevant to my area of expertise. I am a sub-investigator at the Women’s Health and Research Institute of Australia (attached to the Royal Hospital for Women, Sydney) which conducts pharma-sponsored clinical trials.